does bpc 157 help immune system Autoimmune Conditions and Peptide Therapy Vincent Pedre, MD FMCP |

Comparative Dosage Considerations: AHK-Cu vs

No hepatotoxicity has been documented in published human trials lasting up to 12 weeks or in 90-day rodent toxicology studies

What they found: Dose-dependent stimulation of type II collagen (up to 2.5 baseline at 100 nM) Stimulation of aggrecan (up to 1.8 baseline) Inhibition of MMP-13 by ~40 % Partial protection against IL-1-induced matrix degradation Why it matters: It opened a completely new research area for AOD-9604 beyond lipolysis

Pale skin Heart palpitations Shortness of breath A smooth tongue Vision loss Constipation Loss of appetite Diarrhea Gas Vision loss Mental problems like depression, memory loss, or behavioral changes Nerve problems like numbness or tingling, muscle weakness, and problems walking

This is a black box warning for the entire GLP-1 class based on thyroid C-cell tumor findings in rodent studies